Evolus (NASDAQ:EOLS) Earns Buy Rating from HC Wainwright

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $27.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 65.44% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a report on Monday, September 16th. Barclays boosted their target price on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Friday, September 13th.

Evolus Trading Down 2.6 %

NASDAQ EOLS opened at $16.32 on Friday. The stock has a market capitalization of $1.03 billion, a P/E ratio of -17.93 and a beta of 1.31. The business has a 50 day simple moving average of $16.21 and a 200 day simple moving average of $13.66. The company has a debt-to-equity ratio of 6.26, a current ratio of 2.92 and a quick ratio of 2.67. Evolus has a one year low of $7.44 and a one year high of $17.82.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Wednesday, July 31st. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The firm had revenue of $66.91 million for the quarter, compared to the consensus estimate of $65.06 million. Research analysts expect that Evolus will post -0.64 earnings per share for the current year.

Insider Activity

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the sale, the chief marketing officer now owns 82,375 shares in the company, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Evolus news, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Evolus

Several large investors have recently made changes to their positions in EOLS. Quest Partners LLC purchased a new stake in Evolus during the second quarter worth about $43,000. Quarry LP purchased a new stake in shares of Evolus during the 2nd quarter worth approximately $54,000. Profund Advisors LLC bought a new stake in shares of Evolus in the 2nd quarter worth approximately $130,000. Arizona State Retirement System lifted its stake in Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after purchasing an additional 1,253 shares during the last quarter. Finally, ProShare Advisors LLC grew its holdings in Evolus by 9.9% during the first quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock valued at $162,000 after purchasing an additional 1,035 shares during the period. 90.69% of the stock is owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.